Interleukin 22-producing CD4+ T cells in malignant pleural effusion

Cancer Letters

Volumn 326, Issue 1, 2012, Pages 23-32

  Ye, Zhi Jian ^a   Zhou, Qiong ^a   Yin, Wen ^a   Yuan, Ming Li ^a   Yang, Wei Bing ^a   Xiang, Fei ^a   Zhang, Jian Chu ^a   Xin, Jian Bao ^a   Xiong, Xian Zhi ^a   Shi, Huan Zhong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Lung cancer; Malignant pleural effusion; Th22 cells

Indexed keywords

CUTANEOUS T CELL ATTRACTING CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22;

ADENOCARCINOMA; ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOTAXIS; FEMALE; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MODELS, ANIMAL; PLEURAL EFFUSION, MALIGNANT; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84866171319     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.013     Document Type: Article

References (33)

1. Roberts M.E., Neville E., Berrisford R.G., Antunes G., Ali N.J. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010, 65(Suppl. 2):ii32-40.
2. Sugiura S., Ando Y., Minami H., Ando M., Sakai S., Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin. Cancer Res. 1997, 3:47-50.
3. Light R.W. Clinical practice. pleural effusion. N. Engl. J. Med. 2002, 346:1971-1977.
4. Dalbeth N., Lee Y.C. Lymphocytes in pleural disease. Curr. Opin. Pulm. Med. 2005, 11:334-339.
5. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
6. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 2011, 12:383-390.
7. Volpe E., Touzot M., Servant N., Marloie-Provost M.A., Hupe P., Barillot E., Soumelis V. Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production. Blood 2009, 114:3610-3614.
8. Vivier E., Spits H., Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair?. Nat. Rev. Immunol. 2009, 9:229-234.
9. Zenewicz L.A., Flavell R.A. Recent advances in IL-22 biology. Int. Immunol. 2011, 23:159-163.
10. Chang H., Hanawa H., Liu H., Yoshida T., Hayashi M., Watanabe R., Abe S., Toba K., Yoshida K., Elnaggar R., Minagawa S., Okura Y., Kato K., Kodama M., Maruyama H., Miyazaki J., Aizawa Y. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J. Immunol. 2006, 177:3635-3643.
11. Ye Z.J., Zhou Q., Yuan M.L., Du R.H., Yang W.B., Xiong X.Z., Huang B., Shi H.Z. Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. Am. J. Respir. Crit. Care Med. 2012, 185:660-669.
12. Ye Z.J., Zhou Q., Gu Y.Y., Qin S.M., Ma W.L., Xin J.B., Tao X.N., Shi H.Z. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J. Immunol. 2010, 185:6348-6354.
13. Zhang W., Chen Y., Wei H., Zheng C., Sun R., Zhang J., Tian Z. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin. Cancer Res. 2008, 14:6432-6439.
14. Miyagaki T., Sugaya M., Suga H., Kamata M., Ohmatsu H., Fujita H., Asano Y., Tada Y., Kadono T., Sato S. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin. Cancer Res. 2011, 17:7529-7538.
15. Jiang R., Tan Z., Deng L., Chen Y., Xia Y., Gao Y., Wang X., Sun B. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011, 54:900-909.
16. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 2009, 10:857-863.
17. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
18. Xirouchaki N., Tzanakis N., Bouros D., Kyriakou D., Karkavitsas N., Alexandrakis M., Siafakas N.M. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest 2002, 121:815-820.
19. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001, 2:123-128.
20. Qin X.J., Shi H.Z., Deng J.M., Liang Q.L., Jiang J., Ye Z.J. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin. Cancer Res. 2009, 15:2231-2237.
21. Lin Y.C., Shun C.T., Wu M.S., Chen C.C. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res. 2006, 12:7165-7173.
22. Laubli H., Borsig L. Selectins as mediators of lung metastasis. Cancer Microenviron. 2010, 3:97-105.
23. Bernardi R.J., Trump D.L., Yu W.D., McGuire T.F., Hershberger P.A., Johnson C.S. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res. 2001, 7:4164-4173.
24. Romerio F., Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J. 2002, 16:1680-1682.
25. Wu J.J., Zhang X.D., Gillespie S., Hersey P. Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett. 2005, 579:1940-1944.
26. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6:322-327.
27. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
28. Wu P.W., Li J., Kodangattil S.R., Luxenberg D.P., Bennett F., Martino M., Collins M., Dunussi-Joannopoulos K., Gill D.S., Wolfman N.M., Fouser L.A. IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J. Mol. Biol. 2008, 382:1168-1183.
29. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 2002, 277:33676-33682.
30. Weber G.F., Gaertner F.C., Erl W., Janssen K.P., Blechert B., Holzmann B., Weighardt H., Essler M. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J. Immunol. 2006, 177:8266-8272.
31. Zhang F., Shang D., Zhang Y., Tian Y. Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway. Plos One 2011, 6:e20382.
32. Alkhamesi N.A., Ziprin P., Pfistermuller K., Peck D.H., Darzi A.W. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin. Exp. Metastasis 2005, 22:449-459.
33. Slack-Davis J.K., Atkins K.A., Harrer C., Hershey E.D., Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009, 69:1469-1476.